Coverage
-
May 15, 2014
A Maryland federal judge on Wednesday found that Classen Immunotherapies Inc.'s claims that Biogen Idec Inc. infringed its patents for evaluating a vaccine immunization schedule were objectively baseless, dismissing Biogen from the case and granting its request for attorneys' fees.
2 other articles on this case.
View all »